LOS ANGELES--(BUSINESS WIRE)--Capricor, Inc. today announced its most recent capital infusion of nearly $2 million from Broadview Ventures and private individual investors. The funds will be used toward the development of U.S. clinical trials for cardiac therapies based on Capricor’s proprietary mix of stem cells derived from cardiac tissue, which aim to regenerate damaged areas of the heart and improve heart function.
